These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 35298000)
41. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma. Johnson KM; Taslim C; Saund RS; Lessnick SL PLoS One; 2017; 12(11):e0186275. PubMed ID: 29091716 [TBL] [Abstract][Full Text] [Related]
42. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942 [TBL] [Abstract][Full Text] [Related]
43. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Goss KL; Gordon DJ Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma. Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407 [TBL] [Abstract][Full Text] [Related]
45. Plasma hydrogenated cationic detonation nanodiamonds efficiently deliver to human cells in culture functional siRNA targeting the Ewing sarcoma junction oncogene. Bertrand JR; Pioche-Durieu C; Ayala J; Petit T; Girard HA; Malvy CP; Le Cam E; Treussart F; Arnault JC Biomaterials; 2015 Mar; 45():93-8. PubMed ID: 25662499 [TBL] [Abstract][Full Text] [Related]
46. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis. Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088 [TBL] [Abstract][Full Text] [Related]
48. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro. Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994 [TBL] [Abstract][Full Text] [Related]
49. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. González I; Vicent S; de Alava E; Lecanda F J Mol Med (Berl); 2007 Sep; 85(9):1015-29. PubMed ID: 17453169 [TBL] [Abstract][Full Text] [Related]
50. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model. Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560 [TBL] [Abstract][Full Text] [Related]
51. Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Chaturvedi A; Hoffman LM; Jensen CC; Lin YC; Grossmann AH; Randall RL; Lessnick SL; Welm AL; Beckerle MC Mol Biol Cell; 2014 Sep; 25(18):2695-709. PubMed ID: 25057021 [TBL] [Abstract][Full Text] [Related]
52. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846 [TBL] [Abstract][Full Text] [Related]
53. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650 [TBL] [Abstract][Full Text] [Related]
54. Gene expression profile of ewing sarcoma cell lines differing in their EWS-FLI1 fusion type. Bandrés E; Malumbres R; Escalada A; Cubedo E; González I; Honorato B; Zarate R; García-Foncillas J; de Alava E J Pediatr Hematol Oncol; 2005 Oct; 27(10):537-42. PubMed ID: 16217257 [TBL] [Abstract][Full Text] [Related]
55. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553 [TBL] [Abstract][Full Text] [Related]
57. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082 [TBL] [Abstract][Full Text] [Related]
58. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186 [TBL] [Abstract][Full Text] [Related]